In 880 treatment-naive adults with non-cirrhotic chronic hepatitis C in India, 8 weeks of sofosbuvir-velpatasvir was non-inferior to 12 weeks for SVR12 (per-protocol 98·8% vs 99·0%; risk difference 0·2%), with no drug-related serious adverse events.
RCTn = 880
Goel et al. 8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India